tiprankstipranks
Advertisement
Advertisement

ARVN Stock Latest News

Arvinas Shareholders Back Directors, Pay and Auditor Choices
Company AnnouncementsArvinas Shareholders Back Directors, Pay and Auditor Choices
12d ago
8K
ARVN
Arvinas Announces Chief Medical Officer Leadership Transition
PremiumCompany Announcements
Arvinas Announces Chief Medical Officer Leadership Transition
15d ago
8K
ARVN
Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment
PremiumCompany Announcements
Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment
21d ago
8K
ARVN
Rigel closes license agreement for Veppanu
PremiumThe Fly
Rigel closes license agreement for Veppanu
21d ago
PFE
ARVN
Arvinas Reprioritizes Pipeline, Out-Licenses ARV-806 Development
PremiumCompany Announcements
Arvinas Reprioritizes Pipeline, Out-Licenses ARV-806 Development
1M ago
8K
ARVN
Citizens biotech analysts hold a dinnermeeting at ASCO
PremiumThe FlyCitizens biotech analysts hold a dinnermeeting at ASCO
2M ago
AZN
LLY
Arvinas Earnings Call: VEPPANU Win, Pipeline Momentum
Premium
Company Announcements
Arvinas Earnings Call: VEPPANU Win, Pipeline Momentum
2M ago
ARVN
Arvinas price target raised to $16 from $14 at BofA
Premium
The Fly
Arvinas price target raised to $16 from $14 at BofA
2M ago
PFE
ARVN
Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target
PremiumRatings
Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target
2M ago
ARVN
Arvinas price target raised to $18 from $16 at BTIG
PremiumThe Fly
Arvinas price target raised to $18 from $16 at BTIG
2M ago
ARVN
RIGL
Arvinas price target raised to $20 from $18 at Barclays
PremiumThe Fly
Arvinas price target raised to $20 from $18 at Barclays
2M ago
ARVN
Arvinas Faces Key Commercialization Risk as VEPPANU’s Success Hinges on Third‑Party Partner with Pfizer
PremiumCompany Announcements
Arvinas Faces Key Commercialization Risk as VEPPANU’s Success Hinges on Third‑Party Partner with Pfizer
2M ago
ARVN
Arvinas Earnings Call: PROTAC Breakthrough and New Risks
PremiumCompany AnnouncementsArvinas Earnings Call: PROTAC Breakthrough and New Risks
2M ago
ARVN
H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’
Premium
The Fly
H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’
2M ago
PFE
ARVN
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu
Premium
The Fly
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu
2M ago
PFE
ARVN
Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer
PremiumThe Fly
Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer
2M ago
PFE
ARVN
Arvinas Grants Rigel Global Rights to VEPPANU Therapy
PremiumCompany Announcements
Arvinas Grants Rigel Global Rights to VEPPANU Therapy
2M ago
8K
ARVN
Arvinas reports Q1 EPS (90c), consensus (63c)
PremiumThe Fly
Arvinas reports Q1 EPS (90c), consensus (63c)
2M ago
ARVN
Arvinas management to meet with BTIG
PremiumThe Fly
Arvinas management to meet with BTIG
2M ago
ARVN
Guardant Health receives FDA approval for Guardant360 CDx
PremiumThe FlyGuardant Health receives FDA approval for Guardant360 CDx
2M ago
GH
PFE
Arvinas price target raised to $24 from $21 at Citi
Premium
The Fly
Arvinas price target raised to $24 from $21 at Citi
2M ago
ARVN
Arvinas Gains First FDA Approval for Breast Cancer Drug
Premium
Company Announcements
Arvinas Gains First FDA Approval for Breast Cancer Drug
2M ago
8K
ARVN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >